United States Patent 10,597,384: Scope, Claims, and Patent Landscape
What does US 10,597,384 protect?
US 10,597,384 protects a specific crystalline polymorph of a defined small-molecule scaffold:
3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, limited to a monoclinic crystal system with P21/n symmetry and defined unit-cell parameters. It also covers a pharmaceutical composition containing that crystal form and methods of treating cystic fibrosis, including a sub-scope for ΔF508 homozygous patients.
Claim 1 is the anchor. Claims 2-4 are dependent expansions that add downstream use and formulation.
What is the claim-by-claim scope?
Claim 1 (core product claim): crystalline form with tight structural limits
Claim 1 defines the product as:
- Compound identity:
3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
- Crystalline form limitations:
- Monoclinic crystal system
- Space group: P21/n
- Unit cell dimensions (with bracketed uncertainties):
- a = 4.9626 (7) Å
- α = 90°
- b = 12.2994 (18) Å
- β = 93.938 (9)°
- c = 33.075 (4) Å
- γ = 90°
Practical infringement boundary: Claim 1 is not a generic “any polymorph” claim. It is limited to a crystal form that matches the monoclinic P21/n structure and the specified lattice constants (including the numerical ranges implied by the reported measurement uncertainty). A competitor can avoid literal Claim 1 by using a different polymorph, amorphous form, hydrate/solvate, or a polymorph with different space group and/or different unit cell metrics outside the claimed parameter window.
Claim 2 (formulation): composition with the claimed crystal form
Claim 2 protects:
- A pharmaceutical composition comprising:
- the crystal form of Claim 1, plus
- a pharmaceutically acceptable carrier
This is a typical “composition of matter by ingredient limitation” structure. If a manufacturer formulates the same crystalline form (as defined in Claim 1) into tablets, capsules, granules, powders, dispersions, etc., Claim 2 is directly implicated even if the carrier type is conventional.
Not covered by Claim 2: A composition that uses the same active compound in a different solid form (other polymorph/solvate) is not within Claim 2 if it is not the Claim 1 crystal form.
Claim 3 (method of treatment): CF therapy by administering the claimed crystal form
Claim 3 protects:
- A method of treating cystic fibrosis in a patient by
- administering an effective amount of the crystal form of Claim 1
This is a use claim tied to the exact solid form. A cystic fibrosis indication using the compound in another solid form is not a literal match for Claim 3.
Claim 4 (method sub-scope): ΔF508 homozygous patients
Claim 4 further limits Claim 3 to:
- the patient is homozygous for the ΔF508 CFTR mutation
This sub-scope can matter in real-world prescribing because many trials and label populations focus on genotype-defined cohorts. It creates a stronger enforceability posture against products tested and used specifically for that genotype, even where the general CF treatment method may be arguable in scope.
What is the legal “center of gravity” of the patent?
Claim 1 drives most enforcement value because:
- All other claims are dependent on Claim 1’s crystal form.
- The claimed subject matter is not “the molecule,” but “the molecule in a particular solid state.”
In practice, a product that changes only the solid form can fall outside the patent while using essentially the same API chemistry. Conversely, a product that uses the same crystal form will face overlapping product/formulation/method exposure.
What does the crystal-form limitation practically mean for design-around?
The Claim 1 limitation is strict because it uses:
- Space group: P21/n
- Monoclinic system
- Unit cell constants with reported uncertainties
That combination creates a high bar for competitors. Design-around strategies that can avoid literal infringement include:
- Using a different polymorph (different space group or distinct lattice constants).
- Using a solvate or hydrate where lattice parameters shift and often space group changes.
- Using amorphous or “non-crystalline” solid state forms.
- Engineering a crystal form that is reproducibly outside the claimed parameter set.
However, enforcement and validity arguments may still focus on whether alternate forms are “the same” crystal form under claim construction. The patent’s explicit numeric lattice constraints generally strengthen the literal boundary.
How broad is the patent coverage (by claim category)?
| Claim |
Category |
What is limited |
Main coverage risk for a generic/competitor |
| 1 |
Product (crystal form) |
Specific polymorph via space group and unit cell dimensions |
Switching polymorph/solid form can reduce risk |
| 2 |
Product (formulation) |
Composition contains Claim 1 crystal form |
Same crystal form in any carrier likely triggers |
| 3 |
Use (indication) |
CF treatment via administration of Claim 1 crystal |
Use claim tied to solid form |
| 4 |
Use (genotype subset) |
CF treatment in ΔF508 homozygotes |
More targeted genotype reduces defenses based on broader CF use |
Patent landscape: how this blocks the space
The patent is positioned as a crystal-form patent on a specific scaffold. This type of patent usually functions in the landscape as a follow-on “solid-state” barrier around the same API composition that may already exist in earlier patents.
Key landscape dynamics created by US 10,597,384
1) Solid-state exclusivity after early API coverage
Even if earlier patents protect:
- the base molecule,
- salts,
- general compositions,
- or the therapeutic use in cystic fibrosis,
US 10,597,384 can extend exclusivity by creating an additional barrier: a specific polymorph that must be used to land within the claimed product and formulation.
2) Enforcement leverage even with “same drug, different form”
Because Claims 2-4 are tied to the Claim 1 crystal, a competitor who develops a different form to avoid Claim 1 may still face related patent families if other patents cover that alternative solid state. Conversely, if they match the Claim 1 form, the patent becomes harder to avoid because it spans formulation and use.
3) Genotype-limited use claim can support targeted enforcement
Claim 4’s ΔF508 homozygous limitation creates an enforcement hook aligned with clinical and labeling sub-populations. If a competitor markets a CF therapy specifically for ΔF508 homozygotes using the same crystal form, it increases claim fit versus a broader CF population argument.
Where do other patent types likely sit relative to this one?
Without searching the full corpus, the only firm statement available from the claim set is the functional role of this patent: it is a crystal form patent. In real landscapes, such patents typically neighbor:
- Molecule-level patents (structure of the compound) that precede or run in parallel.
- Salt-form patents (if salts were explored).
- Other polymorph/hydrate/solvate patents for the same compound.
- Formulation patents (controlled release, excipients, particle size distribution) that can overlap or compete.
- Method-of-use patents for CF or related indications that may or may not be solid-form-specific.
US 10,597,384 specifically carves out enforceable scope only for the defined monoclinic P21/n lattice variant of the compound.
Claim-driven freedom-to-operate logic
From a freedom-to-operate standpoint, the claims map to three product checkpoints:
- API solid state: does the manufactured API match Claim 1’s unit cell + P21/n?
- Formulation ingredient identity: does the formulation contain the Claim 1 crystal form (even if the carrier differs)?
- Intended use population: is it administered for CF treatment, and in ΔF508 homozygotes to fit Claim 4?
A product that fails the solid-state identity may avoid literal claims 1-4. A product that matches the solid-state identity triggers composition and method claims if marketed for CF treatment consistent with claim scope.
Key Takeaways
- US 10,597,384 is a polymorph patent: Claim 1 is limited to a monoclinic P21/n crystal form defined by specific unit cell parameters (a=4.9626 Å; b=12.2994 Å; c=33.075 Å; β=93.938°; α=γ=90°).
- The patent extends through formulation and use: Claims 2-4 cover compositions containing that exact crystal form and administering it to treat cystic fibrosis, with Claim 4 limited to ΔF508 homozygous patients.
- Design-around is solid-state driven: Avoiding different polymorph/solid forms (different space group or lattice parameters) is the primary literal route out of scope for Claims 1-4.
- Enforcement leverage can be high if the exact crystal form is used: once the manufacturing process yields the Claim 1 solid state, carrier selection and CF use do not remove exposure.
FAQs
1) Does Claim 1 cover the base compound in any form?
No. Claim 1 covers the compound only when it exists as the specified monoclinic P21/n crystal with the stated unit cell dimensions.
2) If a company uses the same compound but a different polymorph, are Claims 2-4 avoided?
Literal coverage for Claims 2-4 depends on whether the product contains the Claim 1 crystal form. A different polymorph can avoid the claim if it is not the same as the claimed crystal by space group and lattice parameters.
3) Is the cystic fibrosis method claim tied to a formulation route?
Claim 3 is tied to administering an effective amount of the Claim 1 crystal form. It does not limit to route or dosage form in the excerpt provided.
4) Why does Claim 4 matter commercially?
Claim 4 narrows method coverage to ΔF508 homozygous patients, aligning enforceability with genotype-defined clinical use and marketing.
5) Can a product avoid infringement by changing excipients?
Changing carriers alone does not avoid Claim 2 if the formulation still contains the Claim 1 crystal form. The critical determinant is the solid-state identity of the API.
References
[1] United States Patent US 10,597,384 (claims provided in prompt).
